welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
- Jaime L. Bohl, MDDr. Bohl is an authority in the area of ...
- Diagnosis, Surveillance, and Treatment Strategies For Familial Adenomatous Polyposis: Rationale and UpdateFamilial adenomatous polyposis is charac...
- Michael A. Valente, DOMichael A. Valente, DO, FACS, FASCRS is ...
- mahipal suraneniTranslational Oncology Lead at PfIzer...
- Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?Colorectal cancer (CRC) is presently one...
- Matthew B. Yurgelun, MDCurrent Positions: Physician, Instructor...
- What are ostomies?https://www.youtube.com/watch?v=VIms6TbN...
English
Portuguese